Cite this: New Options for Refractory Gout Are Showing Promise in Late-Phase Trials - Medscape - July 09, 2024. Comments Commenting is limited to medical professionals.

The primary purpose of the Phase 2 part of the EBO-301 study was to test the validity of multiple patient-reported outcome tools in a treatment refractory population, with the goal of identifying ...

The open-label Phase 1 clinical trial (NCT05130983) is designed to evaluate the safety and efficacy of ExoFlo for the treatment of medically refractory Crohn’s disease.

Considering the Al 2 O 3 –MgO-CaO ternary system phase diagram [8] as well as the chemical composition of dolomite (Table 2), a mixture of Al 2 O 3 and 51% dolomite was prepared in order to obtain a ...

(RTTNews) - GSK plc (GSK, GSK.L) announced Monday that DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free ...

Pasithea Therapeutics announced promising interim results from its Phase 1 study evaluating PAS-004, a next-generation macrocyclic MEK inhibitor, in patients with heavily pre-treated, refractory ...

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study, Therapeutic Advances in Hematology ...

Chimeric antigen receptor (CAR) T-cell therapies have dramatically changed the treatment landscape for the challenging disease of relapsed/refractory large B-cell lymphoma (LBCL). 1-4 TRANSFORM ...

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma Provided by GlobeNewswire Jun 11, 2025 ...

LBA7074Background: Relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) has a poor prognosis. Double-expressor (DEL) or TP53 abnormal r/r DLBCL patients ... I/IIb selective inhibitor ...